Supernus Pharmaceuticals (NASDAQ:SUPN) Stock Rating Lowered by Piper Sandler

Supernus Pharmaceuticals (NASDAQ:SUPN) was downgraded by equities researchers at Piper Sandler from a “strong-buy” rating to a “hold” rating in a report released on Wednesday, Zacks.com reports.

Separately, StockNews.com upgraded Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Wednesday.

Supernus Pharmaceuticals Price Performance

NASDAQ SUPN opened at $31.39 on Wednesday. The firm has a market capitalization of $1.73 billion, a price-to-earnings ratio of -108.24 and a beta of 0.90. The company has a 50 day simple moving average of $27.93 and a 200-day simple moving average of $29.38. Supernus Pharmaceuticals has a 52-week low of $21.99 and a 52-week high of $35.44.

Supernus Pharmaceuticals (NASDAQ:SUPN) last released its quarterly earnings data on Tuesday, August 6th. The specialty pharmaceutical company reported $0.36 earnings per share for the quarter, missing the consensus estimate of $0.39 by ($0.03). The company had revenue of $168.30 million during the quarter, compared to analyst estimates of $148.83 million. Supernus Pharmaceuticals had a net margin of 0.83% and a return on equity of 0.57%. The firm’s quarterly revenue was up 24.1% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.02) EPS. On average, analysts predict that Supernus Pharmaceuticals will post 1.31 EPS for the current year.

Institutional Investors Weigh In On Supernus Pharmaceuticals

A number of large investors have recently bought and sold shares of the business. Congress Wealth Management LLC DE lifted its stake in shares of Supernus Pharmaceuticals by 37.8% in the first quarter. Congress Wealth Management LLC DE now owns 177,801 shares of the specialty pharmaceutical company’s stock worth $6,065,000 after buying an additional 48,750 shares during the last quarter. Sei Investments Co. lifted its position in Supernus Pharmaceuticals by 24.4% during the 1st quarter. Sei Investments Co. now owns 330,580 shares of the specialty pharmaceutical company’s stock worth $11,276,000 after acquiring an additional 64,752 shares during the last quarter. Russell Investments Group Ltd. lifted its position in Supernus Pharmaceuticals by 205.2% during the 1st quarter. Russell Investments Group Ltd. now owns 97,988 shares of the specialty pharmaceutical company’s stock worth $3,342,000 after acquiring an additional 65,880 shares during the last quarter. Schroder Investment Management Group bought a new stake in Supernus Pharmaceuticals during the fourth quarter valued at about $15,685,000. Finally, Vanguard Group Inc. grew its position in shares of Supernus Pharmaceuticals by 2.3% in the fourth quarter. Vanguard Group Inc. now owns 6,214,731 shares of the specialty pharmaceutical company’s stock valued at $179,854,000 after purchasing an additional 142,551 shares during the last quarter.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.